%0 Journal Article %T Advances in anti-HER2 therapy in metastatic breast cancer %A Yao, Minya %A Fu, Peifen %J Chinese Clinical Oncology %D 2018 %B 2018 %9 %! Advances in anti-HER2 therapy in metastatic breast cancer %K %X Though most patients with breast cancer are cured, there are still many patients progressed to metastatic breast cancer (MBC) and some are diagnosed as MBC. Human epidermal growth factor receptor 2 (HER2) is positive in about 20% all breast cancer patients and considered as a poor prognostic factor. The advent of ant-HER2 therapy has prominently prolonged the time of disease progression and survival for HER2-positive MBC patients. This review summarizes the advance in anti-HER2 therapy in HER2-positive MBC according to the phase III clinical trials, and briefly discusses some new agents and anti-HER2 therapy for HER2 low-or non-expression breast cancer patients. %U https://cco.amegroups.org/article/view/20028 %V 7 %N 3 %P 27 %@ 2304-3873